Affordable Access

A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction

Authors
  • Monir, Ejemel
  • Li, Qi
  • Hou, Shurong
  • Schiller, Zachary
  • Wallace, Aaron
  • Amcheslavsky, Alla
  • Yilmaz, Nese Kurt
  • Toomey, Jacqueline R.
  • Schneider, Ryan
  • Ramchetty, Anudeep S.
  • Ganesa, Chandrashekar
  • Cavacini, Lisa
  • Klempner, Mark S.
  • Schiffer, Celia A.
  • Wang, Yan
Publication Date
Aug 21, 2020
Source
[email protected]
Keywords
License
Green
External links

Abstract

COVID-19 caused by SARS-CoV-2 has become a global pandemic requiring the development of interventions for the prevention or treatment to curtail mortality and morbidity. No vaccine to boost mucosal immunity, or as a therapeutic, has yet been developed to SARS-CoV-2. In this study, we discover and characterize a cross-reactive human IgA monoclonal antibody, MAb362. MAb362 binds to both SARS-CoV and SARS-CoV-2 spike proteins and competitively blocks ACE2 receptor binding, by overlapping the ACE2 structural binding epitope. Furthermore, MAb362 IgA neutralizes both pseudotyped SARS-CoV and SARS-CoV-2 in 293 cells expressing ACE2. When converted to secretory IgA, MAb326 also neutralizes authentic SARS-CoV-2 virus while the IgG isotype shows no neutralization. Our results suggest that SARS-CoV-2 specific IgA antibodies, such as MAb362, may provide effective immunity against SARS-CoV-2 by inducing mucosal immunity within the respiratory system, a potentially critical feature of an effective vaccine.

Report this publication

Statistics

Seen <100 times